A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia.
Phase of Trial: Phase I/II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs AT 9283 (Primary)
- Indications Leukaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 20 Sep 2017 New trial record